MedPath

Compassionate Use (CU) of REGN5458 for Patients With Relapsed or Refractory Multiple Myeloma (MM)

Conditions
Multiple Myeloma
Registration Number
NCT05164250
Lead Sponsor
Regeneron Pharmaceuticals
Brief Summary

Provide Compassionate Use' of REGN5458 for Patients with Relapsed or Refractory Multiple Myeloma

Detailed Description

Compassionate Use requests are only being considered in response to Individual Patient Investigational New Drug (IND) applications.

Recruitment & Eligibility

Status
AVAILABLE
Sex
Not specified
Target Recruitment
Not specified
Inclusion Criteria
Exclusion Criteria

Study & Design

Study Type
EXPANDED_ACCESS
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath